lenalidomide has been researched along with Neutropenia in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (20.25) | 29.6817 |
| 2010's | 54 (68.35) | 24.3611 |
| 2020's | 9 (11.39) | 2.80 |
| Authors | Studies |
|---|---|
| Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L | 1 |
| Bachy, E; Bijou, F; Bouabdallah, K; Bouabdallah, R; Cartron, G; Casasnovas, O; Fabiani, B; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Maerevoet, M; Marolleau, JP; Meignan, M; Molina, L; Moluçon-Chabrot, C; Morschhauser, F; Salles, G; Snauwaert, S; Thieblemont, C; Tilly, H; Van den Neste, E; Virelizier, EN | 1 |
| Garcia-Manero, G; Komrokji, RS; Volpe, VO | 1 |
| Ding, K; Jiang, X; Wang, X; Yu, L | 1 |
| Baile, M; Bergua, J; Caballero, D; Campo, E; Dlouhy, I; Enjuanes, A; Espeso, M; González-Barca, E; Grande, C; Jarque, I; López-Guillermo, A; Martín García-Sancho, A; Montes-Moreno, S; Redondo, A; Rodríguez, G; Salar, A; Sancho, JM | 1 |
| Aoki, Y; Minehata, K; Motegi, Y; Uno, S | 1 |
| Amatangelo, M; Arnao, M; Bahlis, NJ; Berdeja, JG; Casas-Avilés, I; Gong, J; Karanes, C; Katz, J; Kim, K; Lamba, M; Li, S; Lonial, S; Maciag, P; Martinez-Lopez, J; Mateos, MV; Oriol, A; Orlowski, RZ; Pawlyn, C; Peluso, T; Pierce, DW; Poon, J; Popat, R; Pourdehnad, M; Quach, H; Ramasamy, K; Richardson, PG; Rodríguez Otero, P; Spirli, A; Trudel, S; Vangsted, AJ; Wong, L | 1 |
| Akdeniz, A; Aslan, C; Aslaner Ak, M; Bağcı, M; Çeneli, Ö; Dağlı, M; Dal, MS; Demircioğlu, S; Doğan, A; Erol, HA; Ertop, Ş; Gedük, A; Gürsoy, V; Keklik Karadağ, F; Merter, M; Oruç Uysal, A; Özkalemkaş, F; Saydam, G; Seçilmiş, S; Tekinalp, A; Terzi Demirsoy, E; Ural, C | 1 |
| Atherton, PJ; Bartlett, NL; Blum, KA; Dueck, AC; Flowers, CR; Habermann, TM; Jung, SH; Leonard, JP; Novotny, PJ; Pitcher, BN; Tan, A; Thanarajasingam, G; Witzig, TE | 1 |
| Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A | 1 |
| Chen, WM; Fu, ZZ; Hu, Y; Huang, XJ; Huang, ZX; Jin, FY; Li, XL; Liao, AJ; Liu, H; Lu, J; Meng, FY; Wang, GM; Wang, XM; Yang, GZ; Zhang, X; Zhong, YP; Zhou, JF | 1 |
| Casadebaig Bravo, ML; Drach, J; Fu, T; Goy, A; Habermann, TM; Kalayoglu Besisik, S; Luigi Zinzani, P; Ramchandren, R; Takeshita, K; Tuscano, JM; Witzig, TE; Zhang, L | 1 |
| Blair, HA | 1 |
| Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL | 1 |
| Almeida, A; Beach, CL; Castaneda, C; Fenaux, P; Garcia-Manero, G; Goldberg, SL; Gröpper, S; Jonasova, A; Santini, V; Vey, N; Zhong, J | 1 |
| Cheson, BD; Khan, N; Ramzi, P; Skarbnik, A; Trivedi, N; Ujjani, C; Wang, H | 1 |
| Calvo-Vidal, MN; Cerchietti, L; Christos, P; Coleman, M; Furman, RR; Hyman, D; Leonard, JP; Martin, P; Rodriguez, A; Ruan, J; Schuster, SJ; Shah, B; Smith, SM; Svoboda, J; Tam, W | 1 |
| Ando, K; André, M; Bartlett, NL; Bouabdallah, K; Bouabdallah, R; Brice, P; Cartron, G; Casasnovas, RO; Daguindau, N; Feugier, P; Flinn, IW; Fowler, NH; Fruchart, C; Gomes da Silva, M; Haioun, C; Larouche, JF; Le Gouill, S; Libby, EN; Liu, D; López-Guillermo, A; Maisonneuve, H; Martin Garcia-Sancho, A; Morschhauser, F; Palomba, ML; Pica, GM; Ribrag, V; Salles, GA; Sehn, LH; Tilly, H; Tobinai, K; Wang, J; Xerri, L; Ysebaert, L; Zachée, P | 1 |
| Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L | 1 |
| Ahmadi, T; Attal, M; Bahlis, N; Basu, S; Chiu, C; Facon, T; Frenzel, L; Goldschmidt, H; Hulin, C; Kobos, R; Kumar, S; Leleu, X; Mace, JR; Macro, M; Moreau, P; Nahi, H; O'Dwyer, M; Orlowski, RZ; Perrot, A; Plesner, T; Qi, M; Quach, H; Raje, N; Tiab, M; Uhlar, CM; Usmani, SZ; Van Rampelbergh, R; Venner, CP; Wang, J; Weisel, K | 1 |
| Bailly, S; Bijou, F; Bonnet, C; Bouabdallah, R; Canioni, D; Cartron, G; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Meignin, V; Morschhauser, F; Nicolas-Virelizier, E; Salles, GA; Snauwaert, S; Thieblemont, C; Tilly, H; Van Eygen, K; Wu, KL | 1 |
| Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF | 1 |
| Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
| Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Chetaille, B; Coso, D; Esterni, B; Ivanov, V; Olive, D; Schiano, JM; Stoppa, AM | 1 |
| Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Afrin, LB; Bentz, TA; Costa, LJ; Fanning, SR; Kistner-Griffin, E; Stephenson, J; Stuart, RK | 1 |
| Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Cheson, BD; Crawford, J | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O | 1 |
| Bogunia-Kubik, K; Butrym, A; Frontkiewicz, D; Gębura, K; Mazur, G; Rybka, J; Łacina, P | 1 |
| Christos, P; Coleman, M; Furman, RR; Katz, O; Leonard, JP; Lewis, J; Martin, P; Rodriguez, A; Ruan, J; Schuster, SJ; Shah, B; Smith, SM; Svoboda, J | 1 |
| Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A | 1 |
| Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C | 1 |
| Chavez, JC; Dalia, S; Kharfan-Dabaja, MA; Komrokji, R; Lancet, J; Locke, FL; Nodzon, L; Pinilla-Ibarz, J; Piris-Villaespesa, M; Powers, J; Sokol, L; Sotomayor, EM; Turba, E | 1 |
| Kimura, M; Kokuryou, T; Matsuoka, T; Mitani, Y; Nakao, T; Okada, K; Usami, E; Yamakawa, M; Yoshimura, T | 1 |
| Carraway, HE; DeZern, A; Gojo, I; Gore, SD; Smith, BD; Zeidan, AM | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Chiozzotto, M; Couto, S; Fabbri, A; Ferreri, AJ; Frezzato, M; Govi, S; Nonis, A; Ponzoni, M; Re, A; Ren, Y; Rocco, AD; Rusconi, C; Sassone, M; Scarfò, L; Spina, M; Stelitano, C; Zaja, F; Zambello, R | 1 |
| Giagounidis, AA; Knight, R; List, AF; Maciejewski, JP; Raza, A; Sekeres, MA; Wride, K | 1 |
| Anderson, KC; Baron, AD; Branagan, AR; Chu, L; Hunter, ZR; Hyman, PM; Ioakimidis, L; Kash, JJ; Munshi, NC; Musto, P; Nawfel, EL; Nunnink, JC; Patterson, CJ; Sharon, DJ; Soumerai, JD; Terjanian, TO; Treon, SP | 1 |
| Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Albrecht, J; Bonilla-Martinez, Z; Okawa, J; Rose, M; Rosenbach, M; Shah, A; Werth, VP | 1 |
| Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Lacy, MQ | 1 |
| González Rodríguez, AP | 1 |
| Argnani, L; Baccarani, M; Berti, E; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Carter, JS; Downs, LS | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR | 1 |
| Adès, L; Banos, A; Beyne-Rauzy, O; Blanc, M; de Botton, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Guerci, A; Kelaidi, C; Lamy, T; Le Bras, F; Rea, D; Schmidt, A; Sebert, M; Turlure, P; Vey, N; Visanica, S | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Komrokji, RS; List, AF | 1 |
| Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R | 1 |
| Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A | 1 |
| Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M | 1 |
| Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J | 1 |
| Buresh, A; Fuchs, D; Heaton, R; Knight, R; Kurtin, S; List, A; Mahadevan, D; Rimsza, L; Roe, DJ; Zeldis, JB | 1 |
| Allred, JB; Byrne, C; Cortes, J; Giles, F; Hogan, WJ; Jones, D; Kantarjian, HM; Ketterling, RP; Lasho, TL; Litzow, MR; McClure, RF; Mesa, RA; Tefferi, A; Thomas, D; Verstovsek, S; Zeldis, JB | 1 |
| Galili, N; Raza, A | 1 |
| Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Jalbrzikowski, J; Jayabalan, D; Lent, R; Leonard, JP; Mark, T; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Zafar, F | 1 |
| Tariman, JD | 1 |
| Colado, E; García-Sanz, R; Mateos, MV; Olazábal, J; San-Miguel, J | 1 |
10 review(s) available for lenalidomide and Neutropenia
| Article | Year |
|---|---|
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
Topics: Anemia; Humans; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Risk Factors | 2023 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Transplantation, Autologous; Vorinostat | 2017 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism | 2016 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2011 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure | 2007 |
47 trial(s) available for lenalidomide and Neutropenia
| Article | Year |
|---|---|
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neutropenia; Rituximab; Thrombocytopenia | 2023 |
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Topics: Administration, Oral; Antibodies; Antineoplastic Agents; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Ubiquitin-Protein Ligases | 2023 |
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Fatigue; Hematologic Neoplasms; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Neutropenia; Rituximab; Thrombosis | 2020 |
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine | 2017 |
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Diarrhea; Exanthema; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Spasm | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy | 2018 |
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Rituximab; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Rituximab; Skin Diseases; Survival Rate; Thalidomide | 2018 |
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival | 2019 |
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Quality of Life; Rituximab; Survival Analysis; Thalidomide | 2015 |
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Peripheral; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Young Adult | 2016 |
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infections; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Salvage Therapy; Thalidomide | 2016 |
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Salvage Therapy; Survival Rate; Thalidomide; Treatment Failure; Treatment Outcome | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quality of Life; Thalidomide; Treatment Outcome | 2017 |
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2008 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Lenalidomide; Male; Middle Aged; Neutropenia; Rituximab; Thalidomide; Thrombocytopenia; Waldenstrom Macroglobulinemia | 2009 |
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Treatment Outcome | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia | 2009 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2009 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neutropenia; Prospective Studies; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2011 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Thalidomide; Topotecan | 2011 |
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neutropenia; Patient Dropouts; Survival Analysis; Thalidomide | 2011 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Quality of Life; Recurrence; Spain; Surveys and Questionnaires; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide | 2012 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Remission Induction; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Thalidomide; Treatment Outcome; Vomiting | 2012 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2002 |
Efficacy of lenalidomide in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Angiogenesis Inhibitors; Bone Marrow; Female; Gene Deletion; Hematopoiesis; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2005 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus Kinase 2; Lenalidomide; Male; Neovascularization, Pathologic; Neutropenia; Platelet Count; Point Mutation; Primary Myelofibrosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Remission Induction; Sequence Deletion; Splenomegaly; Thalidomide; Thrombocytopenia; Time Factors | 2006 |
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thalidomide; Thrombocytopenia | 2006 |
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome | 2007 |
22 other study(ies) available for lenalidomide and Neutropenia
| Article | Year |
|---|---|
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Slovakia | 2022 |
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Follicular; Neutropenia; Treatment Outcome | 2022 |
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Neutropenia; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Tumor Microenvironment; Vincristine | 2023 |
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome | 2023 |
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide | 2023 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Female; Finland; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival; Thalidomide; Treatment Outcome | 2018 |
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Rituximab; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Cycle; Cyclophosphamide; Dexamethasone; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Peptide Hydrolases; Polymorphism, Single Nucleotide; Thalidomide; Ubiquitin-Protein Ligases; Wnt Signaling Pathway | 2015 |
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Internationality; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Prospective Studies; Salvage Therapy; Thalidomide | 2016 |
Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hemoglobins; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Risk Factors; Thalidomide | 2016 |
Lenalidomide for the treatment of resistant discoid lupus erythematosus.
Topics: Adult; Female; Humans; Lenalidomide; Lupus Erythematosus, Discoid; Neutropenia; Thalidomide | 2009 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Thalidomide; Thrombocytopenia; Transfusion Reaction; Treatment Outcome | 2011 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Depression; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prognosis; Recurrence; Risk Factors; Thalidomide; Treatment Outcome; Tremor | 2012 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recombinant Proteins; Thalidomide; Treatment Outcome | 2008 |